Toward Effective Immunotherapy for the Treatment of Malignant Brain Tumors

被引:36
|
作者
Mitchell, Duane A. [1 ,2 ]
Sampson, John H. [1 ,2 ,3 ]
机构
[1] Duke Univ, Med Ctr, Div Neurosurg, Dept Surg,Duke Brain Tumor Immunotherapy Program, Durham, NC 27710 USA
[2] Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA
[3] Duke Univ, Med Ctr, Preston Robert Tisch Brain Tumor Ctr Duke, Durham, NC 27710 USA
关键词
Glioma; immunotherapy; brain tumor; cancer vaccines; dendritic cells; EPIDERMAL-GROWTH-FACTOR; REGULATORY T-CELLS; RECURRENT GLIOBLASTOMA-MULTIFORME; PULSED DENDRITIC CELLS; DONOR LEUKOCYTE INFUSIONS; FACTOR RECEPTOR COMMON; I CLINICAL-TRIAL; PHASE-I; PERIPHERAL-BLOOD; PROSTATE-CANCER;
D O I
10.1016/j.nurt.2009.04.003
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The immunologic treatment of cancer has long been heralded as a targeted molecular therapeutic with the promise of eradicating tumor cells with minimal damage to surrounding normal tissues. However, a demonstrative example of the efficacy of immunotherapy in modulating cancer progression is still lacking for most human cancers. Recent breakthroughs in our understanding of the mechanisms leading to full T-cell activation, and recognition of the importance of overcoming tumor-induced immunosuppressive mechanisms, have shed new light on how to generate effective anti-tumor immune responses in humans, and sparked a renewed and enthusiastic effort to realize the full potential of cancer immunotherapy. The immunologic treatment of invasive malignant brain tumors has not escaped this re-invigorated endeavor, and promising therapies are currently under active investigation in dozens of clinical trials at several institutions worldwide. This review will focus on some of the most important breakthroughs in our understanding of how to generate potent anti-tumor immune responses, and some of the clear challenges that lie ahead in achieving effective immunotherapy for the majority of patients with malignant brain tumors. A review of immunotherapeutic strategies currently under clinical evaluation, as well as an outline of promising novel approaches on the horizon, is included to provide perspective on the active and stalwart progress toward effective immunotherapy for the treatment of malignant brain tumors.
引用
收藏
页码:527 / 538
页数:12
相关论文
共 50 条
  • [31] Immunotherapy for Brain Tumors
    Sampson, John H.
    Maus, Marcela V.
    June, Carl H.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (21) : 2450 - +
  • [32] Immunotherapy for Brain Tumors
    Hoang-Minh, Lan B.
    Mitchell, Duane A.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2018, 19 (11)
  • [33] Immunotherapy of Brain Tumors
    Dutoit, Valerie
    Migliorini, Denis
    Walker, Paul R.
    Dietrich, Pierre-Yves
    IMMUNO-ONCOLOGY, 2015, 42 : 11 - 21
  • [34] Immunotherapy for Brain Tumors
    Lan B. Hoang-Minh
    Duane A. Mitchell
    Current Treatment Options in Oncology, 2018, 19
  • [35] Antibody, T-cell and dendritic cell immunotherapy for malignant brain tumors
    Chandramohan, Vidyalakshmi
    Mitchell, Duane A.
    Johnson, Laura A.
    Sampson, John H.
    Bigner, Darell D.
    FUTURE ONCOLOGY, 2013, 9 (07) : 977 - 990
  • [36] PRINCIPLES AND METHODS OF TREATMENT OF MALIGNANT-TUMORS OF THE BRAIN
    ROMODANOV, AP
    ROMADANOV, SA
    VESTNIK AKADEMII MEDITSINSKIKH NAUK SSSR, 1982, (12): : 77 - 80
  • [37] Recombinant retrovirus vectors for treatment of malignant brain tumors
    Rainov, NG
    Kramm, CM
    VIRAL VECTORS FOR TREATING DISEASES OF THE NERVOUS SYSTEM, 2003, 55 : 185 - 203
  • [38] Oncolytic Viruses as a Platform for the Treatment of Malignant Brain Tumors
    de Sostoa, Jana
    Dutoit, Valerie
    Migliorini, Denis
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (20) : 1 - 22
  • [39] The role of cytotoxic chemotherapy in the treatment of malignant brain tumors
    Kornblith, PL
    SURGICAL NEUROLOGY, 1995, 44 (06): : 551 - 552
  • [40] Current and future strategies for the treatment of malignant brain tumors
    Castro, MG
    Cowen, R
    Williamson, IK
    David, A
    Jimenez-Dalmaroni, MJ
    Yuan, X
    Bigliari, A
    Williams, JC
    Hu, J
    Lowenstein, PR
    PHARMACOLOGY & THERAPEUTICS, 2003, 98 (01) : 71 - 108